Merck fails to win FDA support

Tuesday, March 8, 2011 10:43 AM

Merck, based in Darmstadt, Germany, failed to win FDA support for its multiple sclerosis pill cladribine.

The FDA asked for additional studies to better understand the medicine’s risks. Merck plans to seek an end-of-review meeting with the FDA to determine whether data already collected is sufficient to address the concerns.  

Merck withdrew its European application to sell cladribine last month after regulators said the drug’s benefits do not outweigh its risks. Cladribine, originally a cancer drug, is sold in Russia and Australia under the brand name Movectro.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs